Panelists discuss how unmet needs and future directions for GPRC5D bispecific therapy include improving accessibility, managing long-term safety, and exploring combination strategies to enhance treatment efficacy.
This article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
The panel concludes its discussion with insights on practices for educating health care teams on CAR T-cell therapy administration, highlighting the evolving role of advanced practice providers.
With the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.
Comprehensive cancer centers in Chicago and Atlanta earn national distinction as top performers in patient experience.
Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with GammaTile for Treatment of Newly Diagnosed Metastatic Brain Tumors (ROADS; NCT04365374)
Mehmet S. Copur, MD, and colleagues examine the case of a 65-year-old who presented with back pain and a large T8 spinal mass, leading to a diagnosis of multiple myeloma with spinal cord compromise.
Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.
Closing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.
Panelists discuss advice for nurses collaborating with oncologists in treating patients with HER2+ breast cancer, as well as closing messages for patients receiving treatment and clinicians involved in the care of those with advanced HER2+ breast cancer.
The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
Panelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.
At SGO 2022, Catherine Watson, MD, spoke about how to encourage patients with ovarian cancer to seek genetic testing.
Ghulam Gous, MD, and colleagues report a case of glioblastoma with extensive liver metastases along with a review of previous reports of liver metastasis from glioblastomas and the possible mechanisms of metastasis.
Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.